⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31651759 | 1.00 | — | — | |
| SCHEMBL1369814 | 0.83 | CYP2E1 (0.47) | — | |
| SCHEMBL9846081 | 0.82 | — | — | |
| SCHEMBL27721042 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL19582714 | 0.80 | CYP2E1 (0.43) | — | |
| SCHEMBL7253760 | 0.79 | L3MBTL1 (0.42) | — | |
| SCHEMBL2593605 | 0.79 | — | — | |
| SCHEMBL18230006 | 0.78 | SLC6A4 (0.50) | — | |
| SCHEMBL877689 | 0.78 | CYP2E1 (0.48) | — | |
| SCHEMBL746866 | 0.78 | TDP1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250051345-A1 | PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2025-02-13 | — | — | US | disclosed |
| EP-4448533-A1 | <SUP2/>? <SUB2/>?V?PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CA1.2 ACTIVATORS | Novartis AG (CH) | 2024-10-23 | — | — | EP | disclosed |
| CN-118510782-A | As CaV1.2 Pyridine-3-carboxylic acid ester Compounds of activators | 诺华股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2024115662-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2024-06-06 | — | — | WO | disclosed |
| EP-3601284-B1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | HOFFMANN LA ROCHE (CH) | 2023-12-27 | — | — | EP | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| CN-117024411-A | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-110709392-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-2627648-A1 | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| CN-103108871-A | 17a-hydroxylase/c17,20-lyase inhibitors | NOVARTIS AG | 2013-05-15 | — | — | CN | disclosed |
| CN-102803250-A | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP17 | NOVARTIS AG | 2012-11-28 | — | — | CN | disclosed |
| US-8263635-B2 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011137516-A1 | FLAVONOID DIMERS AND THEIR USE | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2011-11-10 | — | — | WO | disclosed |
| US-20100331326-A1 | Inhibitors of CYP 17 | NOVARTIS AG | 2010-12-30 | — | — | US | disclosed |
| US-7803802-B2 | Substituted amide beta secretase inhibitors | SCHERING CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| WO-2003027105-A1 | SUBSTITUTED 3-PYRIDYL THIOPHENES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027101-A1 | SUBSTITUTED 3-PYRIDYL PYRROLES AND 3-PYRIDYL PYRAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |